Anno: 2009

• Titolo: Health effects of magnetic fields generated from power lines: new clues for an old puzzle
  Riferimento:

  Ann Ist Super Sanita. 2009;45(3):233-7. Review.
  Azione della melatonina:

  50-60 Hz magnetic fields as "possibly carcinogenic to humans" because of the "limited evidence" of carcinogenicity of residential exposure relatively to childhood leukemia, perhaps for subtle differences in the timing of melatonin release.
  Target:

  50-60 Hz magnetic fields.
• Titolo: Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells
  Riferimento:

  Br J Cancer. 2009 Nov 3;101(9):1613-9.
  Azione della melatonina:

  Melatonin(1nM)inhibits aromatase activity and expression by regulating the gene expression of specific aromatase promote region pI.4, and inhibit COX-2 and COX-1 mRNA expression.
  Target:

  COX-2/COX-1 mRNA expression.
• Titolo: Combination of melatonin and a peroxisome proliferator-activated receptor-gamma agonist induces apoptosis in a breast cancer cell line
  Riferimento:

  J Pineal Res. 2009 Jan;46(1):115-6.
  Azione della melatonina:

  No abstract available.
  Target:

  No abstract available.
• Titolo: Total visual blindness is protective against breast cancer
  Riferimento:

  Cancer Causes Control. 2009 Nov;20(9):1753-6.
  Azione della melatonina:

  Blind women withNPL(no perception of light)appear to have a lower risk of breast cancer, compared to blind women with LP. Mechanisms influenced by melatonin or circadian synchronization.
  Target:

  Blindness.
• Titolo: Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs
  Riferimento:

  Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
  Azione della melatonina:

  N(4-chlorobenzoyl)melatonin as a specific AKR1C3 inhibitor validate its role in the proliferation of breast cancer cells.
  Target:

  Aldo-keto reductase (AKR) 1C3
• Titolo: Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens
  Riferimento:

  J Pineal Res. 2009 May;46(4):422-32.
  Azione della melatonina:

  Expression of MT1 and coexpression of MT1/ nestin in invading tumor cells in more advanced tumors suggest an important role for GPCR in pathogenesis of breast cancer.
  Target:

  G-protein-coupled receptor (GPCR).
• Titolo: Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones
  Riferimento:

  Free Radic Biol Med. 2009 Jan 15;46(2):253-62.
  Azione della melatonina:

  NQO2 is a newly discovered binding site (MT3) of melatonin, indicating that it could be a novel target for prevention of breast cancer initiation.
  Target:

  Quinone oxidoreductase 2 (NQO2).
• Titolo: sis in B-lymphoma cells
  Riferimento:

  Ann N Y Acad Sci. 2009 Aug;1171:345-9.
  Azione della melatonina:

  Melatonin is considered a promising antitumor agent, promoting apoptosis in tumor cells and contrasting it in normal cells.
  Target:

  Apoptosis modulator.
• Titolo: Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells
  Riferimento:

  J Pineal Res. 2009 Aug;47(1):23-31.
  Azione della melatonina:

  Treatment of MCF-7 breast cancer cells with melatonin counteracted the increase induced by estradiol almost completely.
  Target:

  Membrane-bound receptor MT1.
• Titolo: Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines
  Riferimento:

  Breast Cancer Res Treat. 2009 Nov;118(2):293-305.
  Azione della melatonina:

  Amplification of the MT1gene in some breast tumors and an inverse correlation with ERalpha, PR and MT1 G protein-coupled melatonin receptor.
  Target:

  Estrogen receptor alpha (Eralpha), progesterone receptor (PR).